# US 2022/0033429 A1 · Mithramycin derivatives having increased selectivity and anti-cancer activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033429 A1
- Document ID: US20220033429A1
- Status: Published application
- Kind: A1
- Application number: 17/278,070
- Filed: 2019-09-20
- Published: 2022-02-03
- Earliest claimed: 2018-09-21
- Assignees: University of Kentucky Research Foundation
- Applicants: University of Kentucky Research Foundation
- Inventors: Jurgen Rohr; Oleg Tsodikov; Markos Leggas; Caixia Hou; Joseph Eckenrode; Prithiba Mitra; Abhisek Mandal
- Web page: https://patentgrep.com/patent/US20220033429A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07H 15/24: Condensed ring systems having three or more rings
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Mithramycin (MTM) short side chain ketone (SK) derivatives and MTM short side chain diketone (SDK) derivatives are provided. The MTM SK and MTM SDK derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM SK and MTM SDK derivatives have increased selectively toward ETS transcription factor.

## Claims

### Claim 1

A mithramycin (MTM) short side chain ketone (SK) derivatives and MTM short side chain diketone (SDK) derivative having the following formula:
MTM-SK/SDK-R2
or a pharmaceutically acceptable salt thereof, wherein R2 can be an amino acid derivative or a dipeptide derivative.

### Claim 2 (depends on 1)

The MTM SK or MTM SDK derivative of claim 1, wherein R is a substituted tryptophan (Trp) derivative.

### Claim 3 (depends on 2)

The MTM SK or MTM SDK derivative of claim 2, having the following formula:

### Claim 4 (depends on 1)

The MTM SK or MTM SDK derivative of claim 1, having the following formula:

### Claim 5 (depends on 1)

The MTM SK or MTM SDK derivative of claim 1, wherein R is a substituted phenylalanine (Phe) derivative.

### Claim 6 (depends on 5)

The MTM SK or MTM SDK derivative of claim 5, having the following formula:

### Claim 7 (depends on 1)

The MTM SK or MTM SDK derivative of claim 1, wherein R is an amino acid dipeptide derivative.

### Claim 8 (depends on 1)

The MTM SK or MTM SDK derivative of claim 1, selected from the formulae consisting of:

### Claim 9 (depends on 1)

A method of treating cancer or neuro-disease in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the MTM SK or MTM SDK derivative or a pharmaceutically acceptable salt thereof of claim 1.

### Claim 10

(canceled)

### Claim 11 (depends on 9)

The method of claim 9, for the treatment of Ewing sarcoma.

### Claim 12 (depends on 9)

The method of claim 9, for the treatment of lung cancer.

### Claim 13 (depends on 9)

The method of claim 9, for the treatment of leukemia or lymphoma.

### Claim 14 (depends on 9)

The method of claim 9, for the treatment of colon cancer.

### Claim 15 (depends on 1)

A method for selectively modulating the activity of a target ETS transcription factor in a patient in need thereof, including administering to the patient a therapeutically effective amount of an MTM SK or MTM SDK derivative or a pharmaceutically acceptable salt thereof of claim 1.
